RecruitMe Clinical Trial

Cemiplimab Survivorship Epidemiology (CASE) Study
Cemiplimab Survivorship Epidemiology (CASE) Study
Sponsor:Regeneron Pharmaceuticals
Enrolling:Male and Female Patients
Minimum Age:18 years old
IRB Number:AAAS3659
U.S. Government ID:NCT03836105
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information:

We are recruiting study subjects who are currently being treated with cemiplimab for Cutaneous Squamous Cell Carcinoma. The purpose of the study is to determine the long-term effectiveness and safety of cemiplimab in patients diagnosed with Cutaneous Squamous Cell Carcinoma (CSCC, a type of skin cancer). We will use the information from the study to better understand the long-term effectiveness and safety of cemiplimab-rwlc in patients diagnosed with CSCC in a non-clinical setting. This is the first survivorship and epidemiology study for patients with CSCC, and represents an important opportunity to shed light on a cancer type that previously has not been well described in the literature.

Do You Qualify?
Are you starting or receiving treatment with cemiplimab for Cutaneous Squamous Cell Carcinoma (CSCC)?YesNo
Are you 18 years of age or older?YesNo
Are you able to understand and complete study-related questionnaires?YesNo
Submit
Cancel
Investigator
Richard Carvajal, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Research Nurse Navigator
Email: cancerclinicaltrials@cumc.columbia.edu
Phone: 212-342-5162